RE:RE:ONCY's pelareorep is now Phase 3-readyBig Pharma and the FDA see the potential pricing of the novel biologic in pelareorep (as a candidate for 13 years of FDA market excluivity) in combination with the generic paclitaxel as a very favorable value proposition, which should result in a rapid marketing approval for an unmet medical need in HR+/HER2 negative breast cancer and therefore a quick follow-on market penetration in this and other cancer indications.
Pelareorep then can be combined with multiple I/O agents including immune checkpoint inhibitors, CAR-T therapy, bisepcifics, ADCs, and small molecules like CDK 4/ and PARP inhibitors. to treat mulitple cancers with unmet medical needs.